Table 2.
Research correlated to the function of Th17 Cell in breast cancer
| Cell line | Treatment | Mice/ Human | In vitro/in vivo | Result | References |
|---|---|---|---|---|---|
| – | Anti-FoxP3 and anti-IL-17 antibodies | Human | In vivo | Increasing the population of Th17 cells in breast cancer tissues enhances anti-tumor immune responses | [26] |
| – | Anti-IFNγ, anti-IL-13, anti-IL-17A, anti-CD8, anti-CD4, anti-CD3 and| anti-CD45 | Human | In vivo | Th17 is a new prognostic compound biomarker in TNBC patients | [106] |
| – | – | Human | In vivo | Serum levels of Th17-related cytokines, including IL-17, TGF-β, and IL-6 in the serum of breast cancer patients, were significantly lower than a healthy individual | [92] |
| MA782 and 4T1 | Anti-CD3 and anti-CD28 antibody | BALB/c mice | In vivo/in vitro | IL-17, one of the most critical cytokines in Th17 cells, was highly expressed in breast tumor tissue | [93] |
| – | Goat polyclonal anti-human IL-17 antibody | Human | In vivo | IL-17-producing cells accumulated in breast cancer tumor tissue, and these cells were a poor prognostic factor | [56] |
| – | Anti-PD-1, anti-CD25, anti-CD45RO, anti-CTLA-4, anti-CD103, anti-GITR, anti-CD8, anti-CD3, anti-Foxp3, anti-CD4and anti-IL-17A antibody | Human | In vivo | Th17 and Treg cells increased significantly in the breast cancer tissue | [96] |
| MCF-7 | Anti-Ly6C, anti-CD11b, anti-CD11c, anti-CD40, anti-Gr-1, and anti-F4 80 | Human/ BALB/c mice | In vivo/in vitro | IL-17 produced in tumor tissue prevented the accumulation of MDSCs in breast cancer tumor tissue by activating STAT3 signaling | [107] |
| JB6 Cl41, MCF7, MEF and MDA-MB231 | MAP3K8 inhibitor, PD98059, anti-ERK1, SP600125, anti-MEK1/2, anti-STAT3, anti-MAP3K8, anti-c-Jun, anti-IL-22R1, anti- JNK1/2, and anti-IL22 antibody | BALB/c mice | In vivo/in vitro | IL-22, by inducing the expression of Pin1 and MAP3K8, increase the rate of angiogenesis, proliferation, and tumorigenesis of tumor cell | [94] |
| – | IL- 17A, anti-CD4, anti-CD25, anti-CD127, IgG2a, G1b, anti-CD3 and anti-CD28 antibody | Human | In vivo | Gradually, with breast cancer progression, Treg cells’ accumulation increased, and the population of Th17 cells decreased | [95] |
| – | Anti-CD28, anti-CCR4, anti-CD39, anti-CD4, anti CD45RA, anti-CD25, anti-CXCR3, anti-CD3, anti-IL-17A, anti-ROR- γt, anti-CCR6and anti-Foxp3 antibody | Human | In vivo | The ectonucleotidase-expressing CD25high + Th17 increases dramatically in tumor tissue and exhibits suppressive function inhibiting CD8 and CD4 cell activation | [97] |
| MDA-MB-231 and MCF-7 | Rabbit anti-sheep anti-rabbit IgG, rabbit anti-human pNF-κB, rabbit anti-human pAKT, Rabbit anti-human IL-17 antibody, rabbit anti-human VEGF, anti-human MMP-9, rabbit anti-human Bcl-2, rabbit anti-human CyclinD1, rabbit anti-human EGFR, anti-human CXCR2, human CXCL1, mouse anti-IL-17A, and mouse anti-CD4 antibody | Human | In vivo/in vitro | Th17 cells regulate CXCL1 expression during cancer progression, and CXCL1 by binding to the CXCR2 receptor could promote the NF-κB/AKT pathway activation, thereby causing the progression of breast cancer | [98] |
| MDA-MB-231 | Anti- TNF-α, anti-IL-17A, anti-CD3, anti- IFN-γ, anti-IL-18Rα, anti CD161, anti-MAIT, anti-Vα7.2 TCR, and anti- CD56 and anti-CD45 antibody | Human | In vitro | Breast tumor cells exposed to bacteria selectively activate Th17-polarized MAIT cells from the mammary ducts, thereby increasing breast cancer progression | [99] |
| – | – | Human | In vivo | A positive relationship between Th17 cells expressing IL-17A and MIF and increasing the expression of both Th17 and MIF increased breast cancer risk | [100] |
| 4T1 | PRI-2191 and Calcitriol anti-mouse CD4, anti-CD335, anti-CD25, anti-CD3, anti-CD19, and anti-CD8a antibody | BALB/c mice | In vivo/in vitro | In young mice treated with PRI-2191, unlike older OVX mice, the expression of Th17, ROR-γt, and ROR-α transcription factors, as well as genes encoding vitamin D receptor and osteopontin, were significantly increased | [108] |
| - | Anti-Ly6G-, anti-CCR6, anti-Vγ1, anti-VEGFR1, anti- CCR2, anti-IL23R, and anti-IL1R1 | KEP, Tcrδ −/− | In vivo | The γδ T cells by production of IL-17A induces neutrophils to promote distant metastases and inhibit CD8 + T Cells and | [101] |
| MCF7, JB6 Cl41 | anti-TPL2, anti-IL-17A, anti- DAB, and anti-PCNA | - | In vitro | IL-17A induces AP-1 activity and the growth and proliferation of breast cancer cells by activating TPL2 | [102] |
| EMT6, MA782,4THM | Anti-IL-I7, anti-CD-3, anti-CD28 | BALB/c | In vitro/ In vivo | IL-17 cytokine significantly increased tumor cell proliferation | [93] |
| 4T1, MDA-MB231, EMT6, MDA-MB435, Hs578t | Anti- CD24, anti- CD29, anti- CD25, anti- CD4, anti-CD45, anti-GPR56, anti-Scara5, anti-Tgf β r1, anti-Smad4, anti-Smad2/3, anti-Smad5, anti-Smad6, anti-NF-κB | BALB/c | In vitro/ In vivo | Treg cells induced IL-17RB expression in breast cancer cells by secreting TGF-β1 | [103] |
| MDA-MB-435 | Anti- CCR3, anti- GAPDH, anti- IkB alpha, anti-VEGF | CD1-nude | In vivo/ In vitro | The IL-17E cytokine has a high ability to induce anti-tumor responses in vitro and in vivo | [104] |
| – | Anti- IL-25, anti-CD45, anti-CD45R, anti-CD3, anti-CD11b, anti-CD4, anti-CD8, anti-CD49b, anti-γδTCR, anti-MHC class II, anti-F4/80, anti-CD25, anti-Ly6G, anti-ST2 and anti-IL-17RB | MMTV-PyMT mice | In vivo/ In vitro | IL-17E increase the growth, proliferation, and metastasis of tumor cells | [105] |